JUL 22, 2017 2:48 PM PDT

Predicting Melanoma Patients' Responses to Immunotherapy

WRITTEN BY: Kara Marker

There’s a new way to predict if cancer patients will respond well to newly FDA-approved immunotherapy drugs for cancer. From the University of California, San Francisco, researchers take a look at melanoma patients and the power of the new predictive biomarker.

 

Malignant Melanoma. Credit: Ed Uthman

Immunotherapy is sometimes applied as a combination of two drugs with different targets. Past studies showed UCSF scientists that whether a cancer patient needs combination therapy or not depends on the number of immune cells in the tumor. More immune cells, the more likely a cancer patient is to benefit from just one immunotherapy drug.

Why would a person respond to one better than the other?

"Combination immunotherapy is super-expensive and very toxic," explained senior author Adil Daud, MD. "You're putting patients at a lot of extra risk if they don't need it, and you can adjust for that risk by knowing in advance who can benefit."

The new assay measures the amount of T cells in tumors so medical professionals can predict how an individual would respond to immunotherapy. T cells work in the immune system to recognize certain proteins on pathogens and cancer cells that distinguishes them from healthy human cells. However, cancer cells hide from the immune system by masquerading as healthy cells, wearing the same protein, PD-L1, on their surface that T cells see and ignore them. Cancer cells then escape undetected, and tumors continue to grow inhibited by the immune system.

Immunotherapy checkpoint inhibitor drugs block either PD-L1 or PD-1, the protein on the surface of T cells that helps them recognize PD-L1. These drugs make cancer visible to the immune system again. But, existing FDA-approved checkpoint inhibitors work for only 20 to 40 percent of cancer patients.

The new UCSF study took tumor samples from 102 melanoma patients and used sorting equipment to calculate the number of T cells in the tumor samples.

"You're pushing on two different gas pedals - PD-1 and CTLA-4," Daud said. CTLA-4 is another checkpoint protein targeted by immunotherapy drugs. "If you're one of those patients with a low number of exhausted T cells, you have a better likelihood of benefitting from both drugs."

During their study, they also saw that women in particular were more likely to benefit from combination immunotherapy. They are also hoping to extend the predictive abilities of the assay to other types of tumors.

The present study was published in the Journal of Clinical Investigation Insight.

Source: UCSF

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
AUG 26, 2021
Coronavirus
Researchers View COVID-19 Progression in a Live Animal Model
AUG 26, 2021
Researchers View COVID-19 Progression in a Live Animal Model
Scientists have used a mouse model to visualize the progression of a SARS-CoV-2 infection as it led to sometimes fatal c ...
SEP 12, 2021
Coronavirus
Real-World, Post-Delta COVID-19 Vaccine Data & Potential Treatment
SEP 12, 2021
Real-World, Post-Delta COVID-19 Vaccine Data & Potential Treatment
New research may have identified a potential treatment or preventive medication for SARS-CoV-2 and other viral infection ...
SEP 14, 2021
Health & Medicine
Graphene-Oxide Based Nanotechnology and Immunology-An Exciting Partnership
SEP 14, 2021
Graphene-Oxide Based Nanotechnology and Immunology-An Exciting Partnership
As treatments and infection control practices surrounding COVID-19 continue to evolve, nanotechnological solutions are b ...
OCT 12, 2021
Drug Discovery & Development
Preventing future pandemics - Scientists developing broadly protective vaccines against coronaviruses
OCT 12, 2021
Preventing future pandemics - Scientists developing broadly protective vaccines against coronaviruses
Researchers at Japan’s Osaka University recently developed and tested a novel vaccine that may protect a ...
OCT 18, 2021
Genetics & Genomics
A Decade After Gene Therapy, SCID Patients Are Doing Well
OCT 18, 2021
A Decade After Gene Therapy, SCID Patients Are Doing Well
For decades, scientists have been trying to find ways to cure disorders that can be traced back to an error in one gene. ...
NOV 10, 2021
Health & Medicine
Zinc for Respiratory Infections
NOV 10, 2021
Zinc for Respiratory Infections
With zinc sales climbing during the pandemic and in vitro studies showing the mineral fights respiratory viruses, includ ...
Loading Comments...